Kans J Med
August 2019
Introduction: The five-year survival rate for patients with glioblastoma (GBM) is low at approximately 4.7%. Radiotherapy plus concomitant and adjuvant temozolomide (TMZ) remains the standard of care.
© LitMetric 2025. All rights reserved.